There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs and Co. LLC are acting as the joint book-running managers for the offering.
Acadia plans to grant the underwriters a 30-day option to purchase up to an additional USD 30m of its common stock.
The shares of common stock described above are being offered by ACADIA pursuant to a shelf registration statement filed by Acadia with the Securities and Exchange Commission that became automatically effective on November 26, 2018.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
Acadia has developed and is commercialising the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials